

1 COVID-19: Rapid Antigen detection for SARS-CoV-2 by lateral flow
2 assay: a national systematic evaluation for mass-testing

3
4 UK COVID-19 Lateral Flow Oversight Team

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

23 **Corresponding Author:**

24 Prof Tim Peto

25 **Senior Author:** Professor Tim Peto, Nuffield Department of Medicine, University of Oxford

26 **Running Title:** Clinical utility of lateral flow SARS-CoV-2 antigen detection

27
28 **Keywords:** coronavirus, COVID-19, SARS-CoV-2, United Kingdom, Public Health, lateral flow, viral antigen
29 detection, testing, national evaluation, LFD, lateral flow tests, lateral flow devices.
30

31 Abstract

32

33 Lateral flow device (LFD) viral antigen immunoassays have been developed around the world as diagnostic tests
34 for SARS-CoV-2 infection. They have been proposed to deliver an infrastructure-light, cost-economical solution
35 giving results within half an hour. Here we report on standardised laboratory evaluations of LFDs, and for those
36 that met the published criteria, field testing in the Falcon-C19 research study and UK pilots (UK COVID-19 testing
37 centres, hospital, schools, armed forces). 4/64 LFDs so far have desirable performance characteristics (Orient
38 Gene, Deepblue, Abbott and *Innova SARS-CoV-2 Antigen Rapid Qualitative Test*). All these LFDs have a viral
39 antigen detection of >90% at 100,000 RNA copies/ml. 8951 Innova LFD tests were performed with a kit failure
40 rate of 5.6% (502/8951, 95% CI: 5.1-6.1), false positive rate of 0.32% (22/6954, 95% CI: 0.20-0.48). Viral antigen
41 detection/sensitivity across the sampling cohort when performed by laboratory scientists (156/198, 95% CI 72.4-
42 84.3) was 78.8%. Our results suggest LFDs have promising performance characteristics for mass population
43 testing and can be used to identify infectious positive individuals. The Innova LFD shows good viral antigen
44 detection/sensitivity with excellent specificity, although kit failure rates and the impact of training are potential
45 issues. These results support the expanded evaluation of LFDs, and assessment of greater access to testing on
46 COVID-19 transmission.

47

48

49 *Funding:* Department of Health and Social Care. University of Oxford. Public Health England Porton Down,
50 Manchester University NHS Foundation Trust, National Institute of Health Research.

51 **Introduction**

52

53 National governments and international organisations including the World Health Organisation (WHO) and
54 European Commission have highlighted the importance of individual testing, mass population testing and
55 subsequent contact tracing to halt the chain of transmission of SARS-CoV-2, the virus responsible for COVID-
56 19.^{1,2,3} The current diagnostic test involves reverse-transcription polymerase chain reaction (RT-PCR) testing of
57 nose/throat swabs in specialised laboratories. Such capacity in the UK is currently estimated at ~500,000
58 tests/day⁴⁻⁷ and this is used with contact tracing procedures and mobile applications to identify close
59 symptomatic contacts of infected symptomatic individuals.⁸⁻¹⁰ However, there are significant challenges in
60 creating testing capacity to identify those with asymptomatic infections or to test contacts of individuals with
61 COVID-19. To date, turnaround time for RT-PCR has been typically slow (>24 hours).

62

63 To better understand and control SARS-CoV-2 transmission, there is an urgent need for large-scale, accurate,
64 affordable and rapid diagnostic testing assays, with the ability to detect infectious individuals. Lateral flow device
65 (LFD) immunoassays can be designed to test for different protein targets and are routinely used in healthcare
66 settings principally as a result of their affordability, ease of use, short turnaround time, and high-test accuracy. In
67 brief, a sample is placed on a conjugation pad where the analyte (or antigen) of interest is bound by conjugated
68 antibodies. The analyte-antibody mix subsequently migrates along a membrane by capillary flow across both
69 'test' and 'control' strips. These strips are coated with antibodies detecting the analyte of interest and a positive
70 test is confirmed by the appearance of coloured control and test lines.¹¹

71

72 Newly developed SARS-CoV-2 antigen LFDs identify the presence of specific viral proteins, using conjugated
73 antibodies to bind spike, envelope, membrane or nucleocapsid proteins. In contrast to the IgM/IgG "antibody
74 tests", these antigen tests directly identify viral proteins, and are not reliant on the host's immune response. In
75 contrast to RT-PCR, results for LFDs are observed in 10-30 minutes depending on the device, providing a
76 window for early interventions to halt the chain of transmission earlier in the disease course when individuals are
77 most infectious.¹²

78

79 To date, many manufacturers have developed first-generation rapid SARS-CoV-2 antigen-detecting LFDs.
80 However, many of these tests have not been independently validated. There is evidence of variable performance
81 when assessing test sensitivity and specificity, although several candidates looked promising on the basis of
82 early data.¹³⁻¹⁵ An independent national evaluation of these devices is important to facilitate population-level or
83 mass testing initiatives globally.

84

85 Here, we report the diagnostic performance of first-generation SARS-CoV-2 antigen-detecting LFD for rapid
86 point-of-care (POC) testing in work that was commissioned by the UK's Department of Health and Social Care
87 (DHSC) from PHE Porton Down and the University of Oxford.

Results

Phase 1

A total of 132 suppliers of SARS-CoV-2 antigen detection LFDs were identified and referred to the DHSC for initial Phase 1 review. Among these, at the time of publication, 64 were selected by the DHSC for further evaluation by the UK lateral flow oversight group.

Phase 2

As part of Phase 2 evaluations, 9,692 LFD tests were performed at PHE Porton Down across the 64 candidate devices as of the 3rd December 2020. 5 LFDs had a kit failure rate above the pre-specified threshold for exclusion (>10%), 17 kits had a false-positive rate below the pre-defined specificity threshold (<97%) and 28 kits a false-negative rate below the LOD threshold (<60% at 10² pfu/m). In total, across all three criteria, nineteen kits performed at a level in accordance with the UK Lateral Flow Oversight Group's *a priori* "prioritisation criteria". All nineteen kits also passed cross-reactivity analyses against seasonal human coronaviruses.

Phase 3

To date, eight LFDs have passed Phase 3a evaluation, namely: *Innova SARS-CoV-2 Antigen Rapid Qualitative Test* (Innova), *Zhejiang Orient Gene Biotech Co. Coronavirus Ag Rapid Test Cassette (Swab)* (Orient Gene), *Anhui Deepblue Medical Technology COVID-19 (Sars-CoV-2) Antigen Test kit (Colloidal Gold)* (Deepblue), *Fortress Diagnostics Coronavirus Ag Rapid Test (Fortress)*, *Roche SD Biosensor Standard Q COVID-19 Ag Test (SD Bio swab)*, *Surescreen Diagnostics SARS-CoV-2 Antigen Rapid Test Cassette (Nasopharyngeal swab (Surescreen))* and *Abbott Panbio COVID-19 Ag Rapid Test Device (Abbott)* (Supplementary Table 1). Three LFDs did not pass 3a evaluation and the remaining LFDs are currently undergoing evaluation. Four LFDs (Deepblue, Innova, Orientgene, Abbott) have passed Phase 3b evaluation (Table 1, Supp Figure 1), one LFD did not pass and the remainder have not been evaluated.

| Viral Load | Average Ct | Innova Number tested/number positive (%) | Abbott Number tested/number positive (%) | Orient Gene Number tested/number positive (%) | Deepblue Number tested/number positive (%) |
|----------------|------------|--|--|---|--|
| >10million | <18 | 5/5 (100) | 1/1 (100) | - | 3/3 (100) |
| 1-10 million | 18-21.5 | 23/23 (100) | 12/13 (92) | 17/17 (100) | 19/19 (100) |
| 0.1-1 million | 21.5-25 | 52/54 (96) | 19/21 (91) | 18/18 (100) | 43/44 (98) |
| 10,000-100,000 | 25-28 | 37/42 (88) | 13/13 (100) | 18/19 (95) | 38/38 (100) |
| 1,000-10,000 | 28-31 | 25/33 (76) | 17/19 (90) | 14/18 (78) | 18/29 (62) |
| 100-1,000 | 31-34.5 | 11/33 (33) | 10/26 (39) | 11/19 (58) | 8/36 (22) |
| <100 | >34.5 | 2/7 (29) | 1/6 (17) | 0/4 (0) | 0/8 (0) |
| Overall | na | 155/197 (79) | 73/99 (74) | 78/95 (82) | 129/177(73) |

Table 1. Results of the Phase 3b evaluations showing viral antigen detection/sensitivity of four LFD tests using dry-swab samples from community sampling. Tests were performed by laboratory scientists. Ct – cycle threshold on RT-PCR.

Extended Innova LFD evaluation (Phases 2-4)

The limit of detection of the Innova LFD (Table 2) was determined as part of Phase 2 evaluations for the Innova test. This analysis consisted of saliva spiked with SARS-CoV-2 with stock of SARS-CoV-2 with a standardised PFU. Under these ideal concentrations, at an estimated PFU of 390/mL, which corresponds to a Ct of ~25, the LFD identified all samples.

| PFU/ml | Ct equivalent | Positive LFD tests/total LFD tests | % positive |
|--------|---------------|------------------------------------|------------|
| 100000 | 16 | 20/20 | 100 |
| 10000 | 19 | 25/25 | 100 |
| 1000 | 23.7 | 65/65 | 100 |
| 390 | 25.2 | 5/5 | 100 |
| 100 | 25.5 | 63/65 | 96 |
| 40 | 28.5 | 3/5 | 60 |
| 20 | 29.3 | 0/5 | 0 |
| 10 | 30.2 | 0/5 | 0 |
| 5 | 31 | 0/5 | 0 |
| 2.5 | 31.7 | 0/5 | 0 |
| 1.2 | 32.5 | 0/5 | 0 |

Table 2. Limit of sensitivity for SARS-CoV-2 detection by the Innova LFD for antigen detection using saliva sample spiked with SARS-CoV-2. Ct - cycle threshold. PFU - plaque forming units.

126
127
128
129
130
131
132
133

Our phase 4 evaluation focused on field testing of the Innova LFD, for which we had a sufficient supply of kits available for wider testing at the time. Device specificity was determined through an analysis of 6954 tests from evaluation phases 2-4. The percentage of false-positives ranged from 0.00-0.49%, with an overall specificity of 99.68%. The false-positive rate was centre-dependent ($p=0.014$, Fisher's exact test). These evaluations noted that where there were challenges in interpreting the results when the test result was "weak" (i.e. the test line was very faint) (Table 3).

| Evaluation Phase | False positives/total number | False positives and 95% confidence interval |
|---|------------------------------|---|
| Phase 2 evaluation | 0/72 | 0.0% (0.0-5.0) |
| Phase 3a evaluation- negative samples | 0/940 | 0.0% (0.0-0.4) |
| Phase 4 evaluation- hospital staff | 1/329* | 0.3% (0.01-1.7) |
| Phase 4 evaluation- armed forces | 0/105 | 0.0% (0.0-3.5) |
| Phase 4 evaluation- PHE staff | 0/209 | 0.0% (0.0-1.8) |
| Phase 4 evaluation- school 1 | 9/1855** | 0.5% (0.2-0.9) |
| Phase 4 evaluation- school 2 + 3 + 4 | 7/2130** | 0.3% (0.1-0.7) |
| Phase 4 evaluation- COVID-19 testing centre | 5/1314*** | 0.4% (0.1-0.9) |
| TOTAL | 22/6954 | 0.3% (0.2-0.5) |

134
135

*This was 1 weak positive result that was also a weak positive on repeating; ** Weak positives result were negative on retesting with Innova; *** Not photographed or repeated. Taken in a setting of prevalence of 14% LFD positive results.

136
137

Table 3. Number of false positives in negative samples in each evaluation stage for the Innova LFD. 95% confidence intervals presented in each case.

138
139
140
141
142
143

Across Phase 2-4 evaluation stages, 8,951 Innova LFD tests were performed, including a diverse cohort of populations as part of Phase 3b and Phase 4 testing, namely out-patient SARS-CoV-2 cases, healthcare staff, armed forces personnel and secondary school children. The overall kit failure rate for the Innova LFD was 5.6% (502/8951, 95% CI: 5.1-6.1) (Table 4). The most common reason for kit failure was poor transfer of the liquid within the device from the reservoir onto the test strip.

| Innova LFD evaluation phase | LFD failures (%) |
|---|------------------|
| Phase 2 negatives | 0/72 (0.0%) |
| Phase 2 positive dilution series | 0/60 (0.0%) |
| Phase 2 positive extended dilution series | 0/155 (0.0%) |
| Phase 2 Swab comparison | 0/187 (0.0%) |
| Phase 3a positives | 13/191 (6.8%) |
| Phase 3a negatives | 50/990 (5.1%) |
| Phase 3b FALCON (Dry swabs- field) | 27/267 (10.1%) |
| Phase 3b FALCON (Dry swabs- lab) | 9/212 (4.2%) |
| Phase 3b FALCON (VTM swabs) | 9/157 (5.7%) |
| Phase 4 hospital staff | 17/358 (4.7%) |
| Phase 4 armed forces | 6/157 (3.8%) |
| Phase 4 PHE staff | 19/212 (8.9%) |
| Phase 4 school 1 | 311/1855 (16.8%) |
| Phase 4 school 2 + 3 + 4 | 14/2132 (0.7%) |
| Phase 4 COVID-19 testing centre | 27/1946 (1.4%) |
| | 502/8951 (5.6%) |

144
145

Table 4. Evaluations of the Innova LFD across Phases 2-4. The table demonstrates the kit failure rate.


146
147
148
149
150
151
152
153
154
155

Viral antigen detection/sensitivity in individuals with confirmed SARS-CoV-2 infection using the Innova LFD was assessed in the Phase 3b evaluation as part of the FALCON-C19 research study. Optimal viral antigen detection/sensitivity when performed by laboratory scientists, was 78.8% (95% CI 72.4-84.3%; 156/198 cases where a paired PCR was performed; see below for differing performance by test operator category). Subgroup analyses showed there were no discernible differences in viral antigen detection/sensitivity in those without symptoms vs. symptomatic individuals (27/41 [65.9%] vs. 95/344 [72.4%], $p=0.38$). We did not find any evidence of associations between LFD positivity and symptoms or past medical history, with the exception of presence of headache (Supplementary Table 2).

156
157
158
159
160

The association between Innova LFD viral antigen detection/sensitivity and estimated viral load/Ct value was explored using the paired RT-PCR VTM swab sample taken at the same time as the swab used for LFD. There was a strong association between viral load detection (RNA copies/mL) determined through RT-PCR and viral antigen detection by LFD (Figure 1). Confirming earlier analyses, sensitivity of LFDs is highest in samples with higher viral loads.^{18,19}

161 Within the 3b FALCON-C19 study, LFDs were also assessed by sampling 150uL of viral transport medium (VTM)
 162 solution instead of using dry swabs; this was associated with poorer performance rate (Supp Figure 2). The use
 163 of dry swabs forms the basis of the manufacturer's instructions for use. This was likely due to a dilution factor
 164 involved in placing the swab first into VTM and then analysing the VTM sample, and highlights potential issues in
 165 generating direct comparisons between LFDs and VTM samples (Supp Figure 2).




166

167 *Figure 1. Association between viral antigen detection/sensitivity and viral load (RNA copies/mL and Ct) in Phase 3b Falcon-C19 study evaluation*
 168 *for dry swabs when performed by trained laboratory scientists and trained healthcare workers. Diamond shows point estimate, with 95%*
 169 *confidence intervals, pooling data from all other categories.*
 170

171

172 *LFD test performance by operator*

173 As part of Phase 3b-4 evaluations, work was performed to report on the effect of the operator on viral antigen
 174 detection/sensitivity in RT-PCR-positive cases using the Innova LFD. Tests were classified according to whether
 175 they were performed by a laboratory scientist, a fully trained research health care worker or by a self-trained lay
 176 individual working at a regional NHS Test and Trace centre. Performance was optimal when the LFD was used
 177 by laboratory scientists (156/198 LFDs positive [78.8%, 95% CI: 72.4-84.3%]) relative to trained healthcare-
 178 workers (156/223 LFDs positive [70.0%, 95% CI: 63.5-75.9%]) and self-trained members of the public given a
 179 protocol (214/372 LFDs positive [57.5%, 95% CI: 52.3-62.6%]; $p < 0.0001$).
 180



181
182

Figure 2. Effect of training and operator on the viral detection/sensitivity of the Innova LFD in COVID-19 PCR-positive patients.

Discussion

We report on our national evaluation of SARS-CoV-2 viral antigen-detecting LFDs, focussing on the *Innova SARS-CoV-2 Antigen Rapid Qualitative Test*, which has a viral antigen detection (sensitivity) of 78.8% when performed by laboratory scientists and a specificity of 99.7%, using RT-PCR as 'gold standard' for positive and negative status. Test performance to detect SARS-CoV-2-positive samples was improved at lower Ct values/higher viral loads, and were >90% at Ct values <25 (equating to ~390 pfu/mL, 100,000 RNA copies/ml) (Supplementary Table 3). There is an expanding body of evidence that suggests viral load/antigen is important as individuals with the highest viral loads are the most infectious,²⁰ and the presence/absence of viral antigens determined by LFDs is more strongly associated with a viral culture than RT-PCR positivity.²¹ In our evaluation, test performance was largely maintained across different settings and cohorts; however, performance was partly operator-dependent and kit failures are not infrequent.

Our experience is that many LFDs entering our national evaluation program do not perform at a level required for mass population deployment and this reflects the literature. To date, an increasing number of evaluations of SARS-CoV-2 antigen-detecting LFD have been published with variable results. A number of LFDs show good²⁴ or acceptable sensitivity and specificity^{28 29}, however, many studies have identified tests with poor sensitivities or specificities.^{30 15}

A challenge for most countries during the SARS-CoV-2 pandemic has been the expansion of capacity for diagnostic testing to support the identification of symptomatic and asymptomatic cases. This would aid in offering testing to "contacts" of COVID-19 and enable targeted testing to better safeguard vulnerable populations e.g. care home residents. Reliance on RT-PCR involves significant infrastructural and specialist human resources to implement at increasing scale. Both the World Health Organisation and European commission have issued guidance supporting wider implementation of antigen-targeting LFDs, and in November, Slovakia became the first country in the world to implement entire population testing using LFDs.^{1,3,31} The UK has similar aspirations to pursue a strategy of mass testing and has implemented a city wide mass testing in Liverpool using the Innova LFD in this study.³²

It is important to note that there are some potential issues with considering RT-PCR as the gold standard test for COVID-19. Many individuals have persisting viral RNA fragments that can linger for weeks-months without any evidence of active viral replication; in this instance a PCR-positive is likely to overcall the "infectious" status of an individual³³ Indeed, when compared to the ability to perform viral culture, data suggest that RT-PCR tends to overestimate the presence of replicating or infectious virions.³⁴

In field testing, performance of the Innova LFD was dependent on the test operator. Individuals who had read a protocol immediately prior to self-sampling did not perform as well as individuals with hands-on training, or clinical laboratory personnel who had performed several hundred LFD tests. Like other operator-dependent procedures, further work is required to determine the duration and content of "training" to derive optimal test performance. We also assume that the use of LFDs to successfully identify individuals with higher viral loads and enabling an earlier diagnosis will be of benefit in interrupting transmission, however, this remains to be proven.

SARS-CoV-2 control will benefit from a variety of testing strategies. This might include those optimised for determining past infection/exposure (e.g. serology), those that are of benefit in determining current/recent infection (e.g. RT-PCR), or those identifying potential infectivity. A combination of approaches incorporating the strengths of each of these tests can be effectively used for individuals and for population-level management of the pandemic. Approaches to testing will remain relevant even when effective vaccines become available as it may take several months for an appreciable effect on transmission to be fully realised.³⁵

In conclusion, we completed late stage evaluations of seven LFDs. We report sensitivities of 70-80% and specificities $\geq 99.7\%$ for each LFD evaluated in phase 3b, which involved testing by laboratory personnel or trained healthcare professionals. To identify patients with higher viral loads (Ct<25), each LFD had >90% sensitivity. Sensitivity was lower in phase 4 evaluations, while specificity was maintained. The simplicity of LFDs, without a requirement for specialist training or equipment, mean that they are an attractive option for mass testing. Future research should focus on post-implementation evaluation of diagnostic accuracy, including the potential benefit of regular serial sampling to improve accuracy and reduce transmission.

239 **Online Methods**

240

241 A phased evaluation of available SARS-CoV-2 antigen LFDs was undertaken.

242

243 **Department of Health and Social Care evaluation (Phase 1 evaluation)**

244

245 The DHSC identified manufacturers supplying SARS-CoV-2 antigen LFDs that could enable mass testing at a
246 population level. A desktop review was performed to ensure there were appropriate instructions for use and to
247 assess manufacturers' claimed performance and manufacturing capabilities.¹⁶

248

249 **Pre-clinical evaluation (Phase 2 evaluation)**

250

251 Pre-clinical evaluation of candidate LFDs was performed by trained laboratory scientists at Public Health England
252 (PHE) Porton Down. LFDs were evaluated against SARS-CoV-2 spiked positive controls and known negative
253 controls, consisting of saliva collected from healthy adult staff volunteers.

254 Pre-defined and publically available "prioritisation" criteria to pass on to the next evaluation phase had to be met
255 for LFDs, consisting of (i) a kit failure rate of <10%; (ii) an analytical specificity of ≥97%, and (iii) an analytical
256 LOD of ≥9 of 15 (60%) at 10² pfu/mL, corresponding to a RT-PCR cycle threshold (Ct) of approximately 25
257 (~100,000 RNA copies/ml); and (iv) lack of cross-reactivity with seasonal coronaviruses to further test analytical
258 specificity.

259

260 **Retrospective secondary care evaluation (Phase 3a evaluation)**

261 Evaluation using patient samples retrospectively was started in August 2020 at PHE Porton Down. Samples were
262 obtained from a secondary healthcare setting (Oxford University Hospitals NHS Foundation Trust).

263 • 1,000 SARS-CoV-2 negative samples: fresh samples held refrigerated were supplied the day after they
264 were tested negative by RT-PCR by the laboratory service at the John Radcliffe Hospital, Oxford, UK.

265 • 200 SARS-CoV-2 positive samples: swabs collected in VTM from patients admitted to hospital during
266 the first wave of the UK pandemic (March-June 2020).¹⁷ These were diluted 1:4 SARS-CoV-2 RT-PCR
267 negative saliva, aliquoted and frozen at -20°C for later use. For each positive sample, in addition to the
268 original diagnostic RT-PCR Ct value, a confirmatory RT-PCR was performed at PHE Porton Down on the
269 diluted sample to determine the new Ct value.

270 **Community research evaluation (Phase 3b evaluation)**

271 We undertook a field evaluation using samples from volunteers in the community in collaboration with the
272 National Institute for Health Research (NIHR) funded CONDOR Platform "COVID-19 National Diagnostic
273 Research and Evaluation Platform". This was performed within the FALCON-C19 study (Facilitating Accelerated
274 Clinical validation Of Novel diagnostics for COVID-19, 20/WA/0169, IRAS 284229), between 17th September and
275 23rd October 2020. This involved the recruitment and re-testing of consenting adults with a RT-PCR-confirmed
276 diagnosis of SARS-CoV-2 infection within 5 days of the original PCR result.

277

278 For the *Innova SARS-CoV-2 Antigen Rapid Qualitative Test*, testing was additionally performed for a subset of
279 samples on-site at four COVID-19 testing centres by trained research staff using the "dry swabs" to evaluate
280 "real-life"/diagnostic performance. Dry swabs are those that are not placed into viral transport medium prior to
281 performing the LFD test.

282

283 **Community field service evaluation (Phase 4 evaluation)**

284

285 Wider field service evaluations were performed within a number of UK institutions and settings. These
286 evaluations utilised the *Innova SARS-CoV-2 Antigen Rapid Qualitative Test*. These institutions included a
287 secondary healthcare setting (John Radcliffe Hospital, Oxford), PHE Porton Down, armed forces members
288 (following an outbreak) and in secondary schools (pupils aged 11-18). Evaluations were also undertaken at
289 regional COVID-19 testing centres as part of an NHS Test and Trace service evaluation involving the general
290 public. The John Radcliffe Hospital, Oxford performed an evaluation as part of their asymptomatic staff screening
291 service using the Respiratory Diagnostic Kit Evaluation ('Red Kite') study (Research Ethics Committee reference:
292 19/NW/0730; North West-Greater Manchester South Research Ethics Committee).

293

294 **Statistical analyses**

295 Fisher's exact and chi-squared tests were used to determine non-random associations between categorical
296 variables. Statistical analyses and data visualisation were performed using R version 4.0.3. Sensitivity and
297 specificity and 95% confidence intervals were calculated using the exact Clopper-Pearson method.

298

299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340

Acknowledgements

The authors thank the participants and their families affected by COVID-19, NHS doctors and nurses and other medical staff, research scientists and support staff at Public Health England, Porton Down, NHS Test and Trace COVID-19 testing centres staff, the NIHR research network, the University of Birmingham medical school, the University of Oxford medical school, the University of Newcastle medical school, NHS Test and Trace and St John Ambulance.

We would like to thank all members of the UK Lateral flow oversight group in contributing data at a challenging time as listed in the web appendix (appendix page 1)

We would like to acknowledge the Department of Health and Social Care, NIHR, University of Manchester and University of Oxford Biomedical Research Council in funding this study.

Viral stocks were supplied by Dr Julian Druce, Doherty Institute, Queensland University, Australia.

The NHS and funders had no role in data collection, analysis or decision to publish.

Funding statement

DSL is supported by the NIHR Community Healthcare MedTech and In vitro Diagnostic Cooperative and the NIHR Applied Research Collaboration (ARC) West Midlands. LYWL, DWC, TEAP, AV, SJH, ASW and HLP are supported by the NIHR Oxford BRC. DWC and NS are supported by the National Institute for Health Research (NIHR) Health Protection Research Unit in Healthcare Associated Infections at University of Oxford (NIHR200915) in partnership with Public Health England (PHE). KKC is Medical Research Foundation-funded. DWC, ASW and TEAP are NIHR Senior Investigators. PCM is funded by the Wellcome Trust (grant 110110/Z/15/Z). Falcon-C19 is a project funded by a National Institute for Health Research (NIHR). DWE is a Robertson Foundation Big Data Institute Fellow. SFL is funded by a Wellcome Trust Clinical Research Fellowship.

The report presents independent research funded by the National Institute for Health Research, Wellcome Trust and the Department of Health. The views expressed in this publication are those of the authors and not necessarily those of the NHS, Wellcome Trust, the National Institute for Health Research, the Department of Health or Public Health England.

Declaration of interest

DWE declares lecture fees from Gilead, outside the submitted work. LYWL has previously received speaker honorarium from the Merck group and Servier for unrelated work. The other authors have nothing to disclose.

341 **References**

- 342
343 1. Diagnostic testing for SARS-CoV-2. <https://www.who.int/publications/i/item/diagnostic-testing-for-sars-cov-2>.
- 344 2. Raffle, A. E., Pollock, A. M. & Harding-Edgar, L. Covid-19 mass testing programmes. *The BMJ* vol. 370 (2020).
- 345 3. Commission steps up actions on testing. *European Commission - European Commission*
- 346 https://ec.europa.eu/commission/presscorner/detail/en/ip_20_2047.
- 347 4. How is the COVID-19 Virus Detected using Real Time RT-PCR? | IAEA. [https://www.iaea.org/newscenter/news/how-is-](https://www.iaea.org/newscenter/news/how-is-the-covid-19-virus-detected-using-real-time-rt-pcr)
- 348 [the-covid-19-virus-detected-using-real-time-rt-pcr](https://www.iaea.org/newscenter/news/how-is-the-covid-19-virus-detected-using-real-time-rt-pcr).
- 349 5. EMERGENCY USE AUTHORIZATION (EUA) SUMMARY COVID-19 RT-PCR TEST (LABORATORY CORPORATION
- 350 OF AMERICA). <https://www.fda.gov/media/136151/download>.
- 351 6. Ghoshal, U., Vasanth, S. & Tejan, N. A guide to laboratory diagnosis of Corona Virus Disease-19 for the
- 352 gastroenterologists. *Indian Journal of Gastroenterology* vol. 39 236–242 (2020).
- 353 7. Coronavirus (COVID-19) in the UK: Testing. <https://coronavirus.data.gov.uk/testing>.
- 354 8. NHS Test and Trace: how it works - GOV.UK. <https://www.gov.uk/guidance/nhs-test-and-trace-how-it-works>.
- 355 9. NHS COVID-19 - NHS. <https://www.nhs.uk/apps-library/nhs-covid-19/>.
- 356 10. Coronavirus (COVID-19): Contact tracing in Scotland | NHS inform. [https://www.nhsinform.scot/illnesses-and-](https://www.nhsinform.scot/illnesses-and-conditions/infections-and-poisoning/coronavirus-covid-19/test-and-protect/coronavirus-covid-19-contact-tracing)
- 357 [conditions/infections-and-poisoning/coronavirus-covid-19/test-and-protect/coronavirus-covid-19-contact-tracing](https://www.nhsinform.scot/illnesses-and-conditions/infections-and-poisoning/coronavirus-covid-19/test-and-protect/coronavirus-covid-19-contact-tracing).
- 358 11. O'Farrell, B. Evolution in Lateral Flow–Based Immunoassay Systems. in *Lateral Flow Immunoassay* 1–33 (Humana
- 359 Press, 2009). doi:10.1007/978-1-59745-240-3_1.
- 360 12. Guglielmi, G. Fast coronavirus tests: what they can and can't do. *Nature* **585**, 496–498 (2020).
- 361 13. Porte, L. *et al.* Evaluation of a novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory
- 362 samples. *Int. J. Infect. Dis.* **99**, 328–333 (2020).
- 363 14. Mertens, P. *et al.* Development and Potential Usefulness of the COVID-19 Ag Respi-Strip Diagnostic Assay in a
- 364 Pandemic Context. *Front. Med.* **7**, 225 (2020).
- 365 15. Denkinger, C. Evaluation of the accuracy, ease of use and limit of detection of novel, rapid, antigen-detecting point-of-care
- 366 diagnostics for SARS-CoV-2. *medRxiv* 2020.10.01.20203836 (2020) doi:10.1101/2020.10.01.20203836.
- 367 16. Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices). *GOV.UK*
- 368 [https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/protocol-for-](https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/protocol-for-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices)
- 369 [evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices](https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/protocol-for-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices).
- 370 17. Eyre, D. W. *et al.* Differential occupational risks to healthcare workers from SARS-CoV-2 observed during a prospective
- 371 observational study. *eLife* **9**, e60675 (2020).
- 372 18. Gremmels, H. *et al.* Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling
- 373 subjects with symptoms of potential SARS-CoV-2 infection. *EClinicalMedicine* **0**, (2020).
- 374 19. Merino-Amador, P. *et al.* Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis
- 375 of SARS-CoV-2 infection. *medRxiv* 2020.11.18.20230375 (2020) doi:10.1101/2020.11.18.20230375.
- 376 20. Singanayagam, A. *et al.* Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of
- 377 COVID-19, England, January to May 2020. *Eurosurveillance* **25**, 2001483 (2020).
- 378 21. Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture | medRxiv.
- 379 <https://www.medrxiv.org/content/10.1101/2020.10.02.20205708v1>.

- 380 22. Cevik, M. *et al.* SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and
381 infectiousness: a systematic review and meta-analysis. *Lancet Microbe* **0**, (2020).
- 382 23. Madewell, Z. J., Yang, Y., Longini, I. M., Halloran, M. E. & Dean, N. E. Household transmission of SARS-CoV-2: a
383 systematic review and meta-analysis of secondary attack rate. *MedRxiv Prepr. Serv. Health Sci.* (2020)
384 doi:10.1101/2020.07.29.20164590.
- 385 24. Nicol, T. *et al.* Assessment of SARS-CoV-2 serological tests for the diagnosis of COVID-19 through the evaluation of
386 three immunoassays: Two automated immunoassays (Euroimmun and Abbott) and one rapid lateral flow immunoassay
387 (NG Biotech). *J. Clin. Virol.* **129**, 104511 (2020).
- 388 25. Igl[□]i, Z. *et al.* Clinical evaluation of the Roche/SD Biosensor rapid antigen test with symptomatic, non-hospitalized
389 patients in a municipal health service drive-through testing site. *medRxiv* 2020.11.18.20234104 (2020)
390 doi:10.1101/2020.11.18.20234104.
- 391 26. Pilarowski, G. *et al.* Performance characteristics of a rapid SARS-CoV-2 antigen detection assay at a public plaza testing
392 site in San Francisco. *medRxiv* 2020.11.02.20223891 (2020) doi:10.1101/2020.11.02.20223891.
- 393 27. Schwob, J.-M. *et al.* Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective
394 comparative clinical trial. *medRxiv* 2020.11.23.20237057 (2020) doi:10.1101/2020.11.23.20237057.
- 395 28. Linares, M. *et al.* Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset
396 of symptoms. *J. Clin. Virol.* **133**, 104659 (2020).
- 397 29. Bulilete, O. *et al.* Evaluation of the PanbioTM rapid antigen test for SARS-CoV-2 in primary health care centers and test
398 sites. *medRxiv* 2020.11.13.20231316 (2020) doi:10.1101/2020.11.13.20231316.
- 399 30. Mak, G. C. *et al.* Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. *J. Clin. Virol. Off. Publ. Pan Am. Soc.*
400 *Clin. Virol.* **129**, 104500 (2020).
- 401 31. The effectiveness of population-wide, rapid antigen test based screening in reducing SARS-CoV-2 infection prevalence in
402 Slovakia. *CMMID Repository* <https://cmmid.github.io/topics/covid19/Slovakia.html> (2020).
- 403 32. Boseley, S. & Elgot, J. Liverpool to pioneer UK's first attempt at mass Covid testing. *The Guardian* (2020).
- 404 33. Carmo, A. *et al.* Clearance and persistence of SARS-CoV-2 RNA in patients with COVID-19. *J. Med. Virol.* **92**, 2227–2231
405 (2020).
- 406 34. La Scola, B. *et al.* Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2
407 patients from infectious disease wards. *Eur. J. Clin. Microbiol. Infect. Dis.* **39**, 1059–1061 (2020).
- 408 35. Mina, M. J., Parker, R. & Larremore, D. B. Rethinking Covid-19 Test Sensitivity — A Strategy for Containment. *N. Engl. J.*
409 *Med.* **0**, null (2020).
- 410 36. Larremore, D. B. *et al.* Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. *medRxiv*
411 (2020) doi:10.1101/2020.06.22.20136309.
- 412 37. Covid-19: Daily coronavirus test plan to cut contacts' 14-day self-isolation. *BBC News* (2020).
- 413 38. November 2020, J. S. NHS staff to get twice-weekly home covid tests with immediate effect. *Health Service Journal*
414 <https://www.hsj.co.uk/acute-care/nhs-staff-to-get-twice-weekly-home-covid-tests-with-immediate-effect/7028943.article>.
- 415

